Belite Bio, Inc
BLTEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeBelite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. At a $5.93B market cap, Belite Bio, Inc ranks as a mid-cap company within healthcare. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.
Market Cap
$5.93B
Beta
-1.23
P/E (TTM)
—
P/E (Fwd)
65.19
EPS (TTM)
$-2.74
EPS (Fwd)
$2.26
ROE
-22.1%
ROA
-15.7%
Cash
—
Total Debt
$0
Free CF
—
52W Change
57.0%
Annual Financials
Cash vs Debt
Where BLTE stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, BLTE finished 9.32% below its 150-day moving average ($157.46) and 11.23% below its 200-day moving average ($160.84). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BLTE overbought or oversold?
At the October 19, 2026 close, BLTE's RSI(14) was 24.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Belite Bio, Inc carries $0 in total debt, a figure that investors should evaluate relative to the company's earnings power. Return on equity stands at -22.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
BLTE's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Belite Bio, Inc and its sector.